SPATA33

Across TCGA pan-cancer cohorts, SPATA33 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA33 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SPATA33 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA33 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

UCEC, GBM, and CCRCC are the cancer types where SPATA33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.638	1.000	.014	12	view →
GBM	DFS	Median	All	0.825	0.612	.005	11	view →
CCRCC	OS	Median	All	1.000	0.693	.039	2	view →
LSCC	OS	Tertile	All	0.756	0.912	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA33–UCEC (OS)

Open the UCEC breakdown →